These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

685 related articles for article (PubMed ID: 29132522)

  • 41. Nutrigenomics analysis reveals that copper deficiency and dietary sucrose up-regulate inflammation, fibrosis and lipogenic pathways in a mature rat model of nonalcoholic fatty liver disease.
    Tallino S; Duffy M; Ralle M; Cortés MP; Latorre M; Burkhead JL
    J Nutr Biochem; 2015 Oct; 26(10):996-1006. PubMed ID: 26033743
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [An Overview of NAFLD/NASH in Japan].
    Kim SR; Kim KI
    Yakugaku Zasshi; 2016; 136(4):565-72. PubMed ID: 27040340
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nonalcoholic Fatty Liver Disease: Review of Management for Primary Care Providers.
    Basu R; Noureddin M; Clark JM
    Mayo Clin Proc; 2022 Sep; 97(9):1700-1716. PubMed ID: 36058582
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.
    Federico A; Zulli C; de Sio I; Del Prete A; Dallio M; Masarone M; Loguercio C
    World J Gastroenterol; 2014 Dec; 20(45):16841-57. PubMed ID: 25492998
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nonalcoholic fatty liver disease burden: Australia, 2019-2030.
    Adams LA; Roberts SK; Strasser SI; Mahady SE; Powell E; Estes C; Razavi H; George J
    J Gastroenterol Hepatol; 2020 Sep; 35(9):1628-1635. PubMed ID: 32048317
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nonalcoholic fatty liver disease: Evolving paradigms.
    Lonardo A; Nascimbeni F; Maurantonio M; Marrazzo A; Rinaldi L; Adinolfi LE
    World J Gastroenterol; 2017 Sep; 23(36):6571-6592. PubMed ID: 29085206
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nonalcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know?
    Budd J; Cusi K
    Am J Med; 2020 May; 133(5):536-543. PubMed ID: 32017891
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver.
    Godinez-Leiva E; Bril F
    Curr Hypertens Rev; 2021; 17(2):94-111. PubMed ID: 33302841
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association of nonalcoholic fatty liver disease and liver cancer.
    Schulz PO; Ferreira FG; Nascimento Mde F; Vieira A; Ribeiro MA; David AI; Szutan LA
    World J Gastroenterol; 2015 Jan; 21(3):913-8. PubMed ID: 25624725
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nonalcoholic Fatty Liver Disease and Fibrosis in Youth Taking Psychotropic Medications: Literature Review, Case Reports, and Management.
    Gracious BL; Bhatt R; Potter C
    J Child Adolesc Psychopharmacol; 2015 Oct; 25(8):602-10. PubMed ID: 26447642
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Management of nonalcoholic fatty liver disease in the Middle East.
    Sanai FM; Abaalkhail F; Hasan F; Farooqi MH; Nahdi NA; Younossi ZM
    World J Gastroenterol; 2020 Jul; 26(25):3528-3541. PubMed ID: 32742124
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms.
    Møller S; Kimer N; Kronborg T; Grandt J; Hove JD; Barløse M; Gluud LL
    Semin Liver Dis; 2021 Aug; 41(3):235-247. PubMed ID: 33992031
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes.
    Cernea S; Cahn A; Raz I
    Expert Rev Clin Pharmacol; 2017 May; 10(5):535-547. PubMed ID: 28276774
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nonalcoholic fatty liver disease - A multisystem disease?
    Mikolasevic I; Milic S; Turk Wensveen T; Grgic I; Jakopcic I; Stimac D; Wensveen F; Orlic L
    World J Gastroenterol; 2016 Nov; 22(43):9488-9505. PubMed ID: 27920470
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Liver fibrosis markers of nonalcoholic steatohepatitis.
    Enomoto H; Bando Y; Nakamura H; Nishiguchi S; Koga M
    World J Gastroenterol; 2015 Jun; 21(24):7427-35. PubMed ID: 26139988
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine.
    Noureddin M; Mato JM; Lu SC
    Exp Biol Med (Maywood); 2015 Jun; 240(6):809-20. PubMed ID: 25873078
    [TBL] [Abstract][Full Text] [Related]  

  • 58. How Would You Manage This Patient With Nonalcoholic Fatty Liver Disease?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
    Libman H; Jiang ZG; Tapper EB; Reynolds EE
    Ann Intern Med; 2019 Aug; 171(3):199-207. PubMed ID: 31382287
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nonalcoholic fatty liver disease.
    Fusillo S; Rudolph B
    Pediatr Rev; 2015 May; 36(5):198-205; quiz 206. PubMed ID: 25934909
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nonalcoholic Steatohepatitis: Histopathology Basics Within a Broader Context.
    Schild MH; Guy CD
    Surg Pathol Clin; 2018 Jun; 11(2):267-285. PubMed ID: 29751874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.